Loading company…
Prelude develops diagnostic tests to guide treatment decisions for breast cancer patients.
Founded in 2009 and based in Laguna Hills, US, Prelude develops diagnostic tests for cancer treatment, with a focus on ductal carcinoma in situ (DCIS). Its DCISionRT test assesses risk profiles and predicts potential benefit from radiation therapy to help guide treatment decisions. The company raised USD 9.28 mn in Series F funding on January 31, 2022, led by Evidity Health Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in